New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
07:18 EDTDYAXDyax announces dosing of first subject in DX-2930 Phase 1b Trial
Dyax announced dosing of the first subject in its Phase 1b clinical study of DX-2930 in hereditary angioedema patients. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of multiple subcutaneous administrations of DX-2930. Dyax is developing DX-2930 as a subcutaneous injection for prevention of HAE attacks. This Phase 1b trial is a multi-center, randomized, double-blind, placebo-controlled, multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of DX-2930 in HAE patients. Approximately 18 subjects will be enrolled into three ascending dose cohorts of DX-2930 or placebo. There will be 4 active drug-treated subjects and 2 placebo-treated subjects per cohort. Each subject will receive two treatments with study drug, separated by two weeks, and undergo approximately 15 weeks of follow-up after the second dose. The company said, "We’ll be utilizing our biomarker assay to assess the possible impact of DX-2930 on exploratory pharmacodynamic parameters such as basal plasma kallikrein activity. We anticipate reporting data from this trial early in 2015.”
News For DYAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 14, 2014
16:23 EDTDYAXDyax files automatic mixed securities shelf
Subscribe for More Information
November 13, 2014
10:42 EDTDYAXSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use